患者

接受塞克昔单抗治疗的患者在治疗开始后的第1周就显示出降低分数的趋势。

临床炎性指标（SPARCC）

在第12周时。接受安慰剂的患者显示出5.8点的下降。

接受塞克昔单抗治疗的患者显示出9点的下降。

What did this study find?

患者被随机分配至塞克昔单抗150 mg或300 mg，这取决于其皮肤疾病的严重程度。

患者被随机分配至塞克昔单抗150 mg或300 mg，这取决于其皮肤疾病的严重程度。

患者被随机分配至塞克昔单抗150 mg或300 mg，这取决于其皮肤疾病的严重程度。

The analysis compared ultrasound scores of synovitis caused by PsA, using a PDUS standardized and validated ultrasound scoring system.

Secukinumab is a type of medication called a biologic. It helps reduce inflammation by blocking one of the proteins that activates inflammatory cells.

Patients were given either 150 mg or 300 mg secukinumab based on the severity of their skin disease.

PsA is a type of inflammatory arthritis that occurs in some patients with psoriasis. Inflammation is one way the body fights infection, but it can also become a problem if it occurs more than needed or happens without a good reason. Research suggests continued inflammation from PsA can result in joint damage.

The inflammation of the lining of the joints is called synovitis. Synovitis is one of the manifestations of PsA.

The American College of Rheumatology (ACR) scoring system is used to measure symptom improvement in arthritis. It takes into account the number of tender and swollen joints as well as functional ability and other markers of inflammation.

ACR20 (American College of Rheumatology 20%) response: measures an improvement of 20% in the number of tender and swollen joints, functional ability and other markers of inflammation.

ACR50 (American College of Rheumatology 50%) response: measures an improvement of 50% in the number of tender and swollen joints, functional ability and other markers of inflammation.

Patients treated with secukinumab had a reduction in their scores as early as Week 1 of treatment. Clinical enthesitis score (SPARCC) 12 weeks. Patients who were given a placebo saw a 5.8-point reduction.

Patients treated with secukinumab had a 9-point reduction in their ultrasound score of synovitis after the proteins that activates inflammatory cells.4

Secukinumab is a type of medication called a biologic. It helps reduce inflammation by blocking one of the proteins that activates inflammatory cells.4

Doctors use different innovative and sensitive imaging techniques to visualize inflammation inside the area of the body.2 In PsA, inflammation results in swollen and painful joints and tendons, and can happen in any area of the body.2

Inflammation:

Psoriatic Arthritis:

Enthesitis:

Synovitis:

Biologic:

Table: Percentage of patients with active PsA as measured by ACR and PsDAI (Psoriatic Arthritis Disease Activity Index) scores

<table>
<thead>
<tr>
<th>Group</th>
<th>Percentage of patients with active PsA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>68%</td>
</tr>
<tr>
<td>Secukinumab</td>
<td>34%</td>
</tr>
</tbody>
</table>

The safety of secukinumab was consistent with previous studies in psoriasis and PsA.

### Glossary

**Psoriatic Arthritis (PsA)**: A type of inflammatory arthritis that occurs in some patients with psoriasis.

**PsDAI (Psoriatic Arthritis Disease Activity Index)**: A measure of disease activity in PsA.

**ACR (American College of Rheumatology)**: A scoring system used to measure symptom improvement in arthritis.

**Synovitis**: Inflammation of the lining of the joints.

**Enthesitis**: Inflammation where the tendons join the bone.

**Biologic**: A type of medication used to treat inflammatory conditions.

**PDUS (Power Doppler ultrasonography)**: A specific ultrasound technique that can be used to measure synovitis.

### Why was this study done?

The manuscript was based on a submitted abstract to the Annual Scientific Meeting of the American College of Rheumatology.

### Who sponsored this study?

Novartis

### Further information

More on this study can be found here:

https://clinicaltrials.gov/ct2/show/NCT02662985

[Link to the study summary provided by Novartis.]

[Link to the full abstract provided by Novartis.]

[Link to the study press release provided by Novartis.]

[Link to other relevant media resources provided by Novartis.]

### References


